DCTH
EquityDelcath Systems, Inc.
Health Care · Medical Devices
$8.90
+8.90 (+0.00%)
Open
N/A
Day Range
$8.49 - $9.11
52W Range
$8.12 - $18.23
Volume
945K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Delcath Systems Q4 Earnings Call Highlights
Delcath (DCTH) Q4 2025 Earnings Call Transcript
Delcath Systems, Inc. Q4 2025 Earnings Call Summary
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
www.delcath.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for DCTH
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for DCTH.